Zentraler Deafferenzierungsschmerz: Klinisches Bild und Therapie

Zusammenfassung

Zentraler Deafferenzierungsschmerz kann grundsätzlich nach jeder Läsion im Verlauf der zentralen Schmerzbahn entstehen. Leitsymptom ist ein konstanter oder intermittierender Schmerz mit sensiblen Auffälligkeiten im schmerzhaften Körperteil. Eine Allodynie ist pathognomonisch für alle Arten des neuropathischen Schmerzes; sie ist in mehr als der Hälfte der Fälle von zentralem Deafferenzierungsschmerz vorhanden. Realistisches Therapieziel ist eine Linderung der Schmerzen, Schmerzfreiheit hingegen ist selten erreichbar. Es gibt nur wenige kontrollierte Studien an relativ kleinen Patientenkollektiven. Die Wirksamkeit von Amitriptylin und Lamotrigin in der Behandlung zentraler Deafferenzierungsschmerzen wurde in plazebokontrollierten Studien nachgewiesen. Diese Substanzen sind daher Mittel der ersten Wahl. Für Gabapentin zeigte eine offene Studie eine Wirksamkeit, ebenso für Mexiletin als Add-on-Therapie zusammen mit Antidepressiva. Häufig ist eine Kombinationstherapie notwendig. Sie sollte immer begleitet sein von Rehabilitationsmaßnahmen, insbesondere Bewegungstherapie, und der Beseitigung zusätzlicher nozizeptiver Schmerzquellen. Nach Ausschöpfen aller medikamentösen Behandlungsoptionen verbleiben invasive Therapiemaßnahmen als Ultima Ratio, z. B. Thalamusstimulation, Motokortexstimulation, Rückenmarkstimulation. Ihre Erfolge sind jedoch häufig zeitlich limitiert.

Abstract

Central pain can occur following lesions anywhere in the spinothalamic pathway and its corticopetal projections. It is characterized by constant or intermitted pain in association with sensory abnormalities in the painful part of the body. Allodynia is a classic hallmark that is present in more than 50 % of patients with central pain. Pain reduction rather than pain relief is the goal of the treatment. Randomized controlled trials are rare and include only small numbers of patients. Amitriptyline and lamotrigine have proven to be effective in placebo-controlled randomised trials and are the drugs of first choice. Gabapentin has demonstrated promising effects in an open study, as well as Mexiletine added-on to antidepressants. Combination therapy is often needed and should always be accompanied by a comprehensive rehabilitation program and an accurate search for and treatment of accompanying sources of nociceptive pain. If drug treatment fails, surgical interventions like deep brain stimulation, cortical stimulation, or spinal cord stimulation can be the ultima ratio. Unfortunately, with these later therapies, recurrence of pain after months or years is common.

Central pain - neuropathic pain - mechanisms - therapy

Literatur

• 1 Dejerine J, Roussy J. Le syndrome thalamique.  Rev Neurol. 1906;  14 521-532
• 2 Foix C, Chavany J-A, Lévy M. Syndrome pseudo-thalamique d'origine pariétale. Lésion de l'artère du sillon interpariétal. Paris: CR Soc Neurol 1927: 168-175
• 3 Cassinari V, Pagni C A. Central pain. A neurosurgical survey. Cambridge (MA); Harvard University Press 1969
• 4 Bowsher D, Leijon G, Thuomas K A. Central poststroke pain: correlation of MRI with clinical pain characteristics and sensory abnormalities.  Neurology. 1998;  51 1352-1358
• 5 Kumral E, Kocaer T, Ertübey N. et al . Thalamic hemorrhage: a prospective study of 100 patients.  Stroke. 1995;  26 964-970
• 6 Nasreddine Z S, Saver J L. Pain after thalamic stroke: right diencephalic predominance and clinical features in 180 patients.  Neurology. 1997;  48 1196-1199
• 7 Andersen G, Vestergaard K, Ingeman-Nielsen M. et al . Incidence of central post-stroke pain.  Pain. 1995;  61 187-193
• 8 Ringelstein E B. Zentraler Deafferenzierungsschmerz (Thalamusschmerz). In: Gralow I, Husstedt IW, Bothe HW, Evers S, Hürter A, Schilgen M (Hrsg) Schmerztherapie interdisziplinär. Stuttgart; Schattauer 2002: 208-219
• 9 Bowsher D. Central pain: clinical and physiological characteristics.  J Neurol Neurosurg Psychiatry. 1996;  61 62-69
• 10 Leijon G, Boivie J, Johansson I. Central post-stroke pain - neurological symptoms and pain characteristics.  Pain. 1989;  36 13-25
• 11 Gonzales G R. Suicide in central pain patients.  Neurology. 1994;  44, Suppl 2 A318
• 12 Canavero S, Bonicalzi V, Massa-Micon B. Central neurogenic pruritus: a literature review.  Acta Neurol Belg. 1997;  97 244-257
• 13 Eide P K, Jorum E, Stenehjem A E. Somatosensory findings in patients with spinal cord injury and central dysaesthesia pain.  J Neurol Neurosurg Psychiatry. 1996;  60 411-415
• 14 Christensen M D, Hulsebosch C E. Chronic central apin after spinal cord injury.  Neurotrauma. 1997;  14 517-537
• 15 Davis K D, Kiss Z H, Tasker R R. et al . Thalamic stimulation-evoked sensations in chronic pain patients and in non-pain (movement disorder) patients.  J Neurophysiol. 1996;  75 1026-1037
• 16 Canavero S, Bonicalzi V. The neurochemistry of central pain: evidence from clinical studies, hypothesis and therapeutic implications.  Pain. 1998;  74 109-114
• 17 Budd K. The use of the opiate antagonist, haloxone, in the treatment of intractable pain.  Neuropeptides. 1985;  5 410-422
• 18 Arner S, Meyerson B A. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain.  Pain. 1988;  33 11-23
• 19 Yamamoto T, Katayama Y, Hirayama T. et al . Pharmacological classification of central post-stroke pain: comparison with the results of chronic motor cortex stimulation.  Pain. 1997;  72 5-12
• 20 Attal N, Guirimand F, Brasseur L. et al . Effects of IV morphine in central pain.  Neurology. 2002;  58 554-563
• 21 Rowbotham M, Twilling L, Davies P S. et al . Oral opioid therapy for chronic peripheral and central neuropathic pain.  New Engl J Med. 2003;  348 1223-1232
• 22 Leijon G, Boivie J. Central post-stroke pain - a controlled trial of amitriptyline and carbamazepine.  Pain. 1989;  36 27-36
• 23 Lampl C, Yazdi K, Röper C. Amitriptyline in the prophylaxis of central poststroke pain.  Stroke. 2003;  33 3030-3032
• 24 Schott G D. From thalamic syndrome to central poststroke pain.  J Neurol Neurosurg Psychiatry. 1995;  61 560-564
• 25 Bowsher D. The management of central post-stroke pain.  Postgrad Med J. 1995;  71 598-604
• 26 Gonzales G R. Central pain: diagnosis and treatment strategies.  Neurology. 1995;  45, Suppl 9 S11-16
• 27 Vestergaard K, Andersen G, Jensen T S. Treatment of central post-stroke pain with a selective serotonin reuptake inhibitor.  Eur J Neurol. 1996;  3, Suppl 5 169
• 28 Shimodozono M, Kawahira K, Kamishita T. et al . Reduction of central poststroke pain with the selective serotonin reuptake inhibitor fluvoxamine.  Intern J Neuroscience. 2002;  112 1173-1181
• 29 Cantor F K. Phenytoin treatment of thalamic pain.  Br Med J. 1972;  840 590
• 30 Mladinich E K. Diphenylhydantoin in the Wallenberg syndrome.  JAMA. 1974;  230 1230-1232
• 31 Agnew D C, Goldberg V D. A brief trial of phenytoin therapy for thalamic pain.  Bull L A Neurol Soc. 1976;  41 9-12
• 32 Vestergaard K, Andersen G, Gottrup H. et al . Lamotrigine for central poststroke pain. A randomized controlled trial.  Neurology. 2001;  56 184-190
• 33 Canavero S, Bonicalzi V. Lamotrigine control of central pain.  Pain. 1996;  68 179-181
• 34 Carrieri P B, Provitera V, Lavorgna L. et al . Response of thalamic pain syndrome to lamotrigine.  Eur J Neurol. 1998;  5 625-626
• 35 Attal N, Parker F, Brasseur L. et al . Effects of gabapentin on the different components of neuropathic pain syndromes: a pilot study.  Europ Neurol. 1998;  40 191-200
• 36 Holtom N. Gabapentin for treatment of thalamic pain syndrome.  Palliat Med. 2000;  14 167
• 37 Herman R M, D'Luzansky S C, Ippolito R. Intrathecal baclofen suppresses central pain in patients with spinal lesions: a pilot study.  Clin J Pain. 1992;  8 338-345
• 38 Taira T, Tanikawa T, Kawamura H. et al . Spinal intrathecal baclofen suppresses central pain after a stroke.  J Neurol Neurosurg Psychiatry. 1994;  57 381-382
• 39 Taira T, Kawamura H, Tanikawa T. et al . A new approach to control central deafferentation pain: spinal intrathecal baclofen.  Stereotactic Funct Neurosurg. 1995;  65 101-105
• 40 Awerbuch G I, Sandyk R. Mexiletine for thalamic pain syndrome.  Int J Neurosci. 1990;  55 129-133
• 41 Chiou-Tan F Y, Tuel S M, Johnson J C. et al . Effect of mexiletine on spinal cord injury dysesthetic pain.  Am J Phys Med Rehabil. 1996;  75 84-87
• 42 Bowsher D, Nurmikko T. Central post-stroke pain. Drug treatment options.  CNS Drugs. 1996;  5 160-165
• 43 Backonja M, Arndt G, Gombar K A. et al . Response of chronic neuropathic pain syndromes to ketamine: a preliminary study.  Pain. 1994;  56 51-57
• 44 Canavero S, Bonicalzi V, Pagni C A. et al . Propofol analgesia in central pain: preliminary clinical observations.  J Neurol. 1995;  242 561-567
• 45 Attal N, Gaudé V, Brasseur L. et al . Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study.  Neurology. 2000;  54 564-574
• 46 Kumar K, Toth C, Math R K. Deep brain stimulation for intractable pain: a 15-year experience.  Neurosurgery. 1997;  40 736-747
• 47 Fujii M, Ohmoto Y, Kitahara T. et al . Motor cortex stimulation therapy in patients with thalamic pain.  No-Shinkei-Geka. 1997;  25 315-319 ,  (englischer Abstract)
• 48 Katayama Y, Fukaya C, Yamamoto T. Post-stroke pain control by chronic motor cortex stimulation: neurological characteristics prediciting a favourable response.  J Neurosurg. 1998;  98 585-591
• 49 Mertens P, Nuty C, Sindou M. et al . Precentral cortex stimulation for treatment of central neuropathic pain. Results of a prospective study in a 20-patients series.  Stereotact Funct Neurosurg. 1999;  73 122-125
• 50 Katayama Y, Yamamoto T, Kobayashi K. et al . Deep brain and motor cortex stimulation for post-stroke movement disorders and post-stroke pain.  Acta Neurochir Suppl. 2003;  87 121-123
• 51 Migita K, Uozumi T, Arita K. et al . Transcranial magnetic stimulation of motor cortex in patients with central pain.  Neurosurgery. 1995;  36 1037-1040
• 52 Taub E, Munz M, Tasker R R. Chronic electrical stimulation of the gasserian ganglion for the relief of pain in a series of 34 patients.  J Neurosurg. 1997;  86 197-202
• 53 Finnerup N B, Yezierski R P, Sang C N. et al .Treatment of spinal cord injury pain. Pain Clinical Updates, International Association for the Study of Pain. 2001, June 9 (2). Available at: http://www.iasp-pain.org/PCU01-2.html
• 54 Peyron R, Garcia-Larrea L, Deiber M P. et al . Electrical stimulation of precentral cortical area in the treatment of central pain: electrophyiological and PET study.  Pain. 1995;  62 275-286
• 55 Ebert B, Andersen S, Krosgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl D-aspartate (NMDA) antagonists in the rat cortex and spinal cord.  Neurosci Lett. 2000;  295 21-24
• 56 Stringer M, Makin M K, Miles J. et al . D-Morphine, but not l-morphine, has low micromolecular affinity for the non-competitive N-methyl D-aspartate site in the rat forebrain. Possible clinical implications for the management of neuropathic pain.  Neurosci Lett. 2000;  295 21-24